|
|
 |
|
Viewing report
|
|
|
|
Diabetes Market Forecast to 2015
Cutting Edge Information, Jan 2010, Pages: 324
Gain instant access to the most up-to-date information on the diabetes market. Scour in-depth profiles of brands and diabetes drug makers to target and seize market share, optimize return on investment, prove the value of your assets, and set proactive brand strategies.
In addition to market forecasts, you'll find primary data from physicians worldwide as well as industry leaders in R&D and marketing. Their input provides knowledgeable, fresh insights on emerging treatments and unmet needs in the diabetes space.
Get accurate, honest market outlooks
Save money and valuable time with sales projections, patent information and clinical data - all in context, so you can compare brands, classes and companies.
Answer critical questions about your diabetes portfolio:
- Are you entering the diabetes market - or expanding your current portfolio?
- How does your developing drug compare to brands on the market?
- Does your drug stand a chance?
- Are you working on another DPP-4 inhibitor or GLP-1 analog - and ignoring a market push toward novel therapies?
- Have you been hit by the FDA's cardiovascular guidelines?
- Are you adequately prepared for regulatory review?
- Are you trying to out-license a diabetes product?
- How will your early-stage diabetes compound fare in tomorrow's market?
- Is there room for your drug, too?
Uncover Anti-diabetes Market Threats and Opportunities
Equip your teams with the most comprehensive forecast of the diabetes market from today’s major players to tomorrow’s blockbusters.
Product Breakdown:
45 anti-diabetes drugs in all major classes
37 anti-diabetes
8 for diabetic complications
Product Profile Components:
- Product history
- Competitive and strategic positioning
- Market growth opportunities
- Sales history and projections
- Drug’s materiality to company
- US patents and market exclusivities
- Analysis of clinical trial history
Drug Manufacturer Profiles
For top 10 diabetes companies:
- Diabetes market position/ranking
- Market forecast
- Strengths analysis
- Growth areas analysis
- Market-changing opportunities analysis
- Key products breakdown
Market Outlook
Although the drug’s patents and exclusivity have expired, sales for Amaryl remain strong. Sales are expected to slowly decline but should remain above the $500 million mark for the foreseeable future, mainly buffered by international markets, as sulfonylurea have lost popularity in the United States for various safety and efficacy reasons. Impending GLP-1 approvals could impact this figure in the coming years, especially when considering their safety when used in conjunction with Amaryl. As of December 2008, Amaryl was listed as the leading oral ant diabetic drug in Japan in terms of number of patients treated.
The following is an excerpt from Chapter 4, “Physician Perspectives on the Diabetes Market.”
Greatest Unmet Needs: Type 1 Diabetes
Analysts collected physicians’ views on the greatest needs of both types of diabetes. Figure 4.5 shows an overall breakout of the greatest unmet needs for Type 1. Forty-four percent of responding physicians feel that new science is the greatest unmet need. The next greatest need, according to survey data, is patient adherence: 26% of respondents believe it the most pressing impediment to better treatment. Of course, new science that allows for easier, more convenient or more effective glucose control could go a long ways toward improving adherence. While only 12% of physicians list glucose control explicitly as the greatest need, this small share could stem from many physicians are looking at a bigger picture of glucose control through new science, rather than glucose control not being an issue.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Type 2 Diabetes Market Dynamics: Impact of Januvia and Other DPP-IV Inhibitors
Competitor Analysis: Diabetes Drug Pipeline
The Diabetes Market Outlook To 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
Opportunities Assessment for Diabetes Therapeutics: South Korea
Pipeline Insight: Non-Insulin Antidiabetics - Type 2 Diabetes Unlikely To Develop Into a Switch Market
Innovations in the Management of Diabetes: Next Generation Treatments and Market Dynamics
The Global Diabetes Market: Therapeutics, Diagnostics and Complications
U.S. Diabetes Pipeline Outlook
The Diabetes Market Outlook to 2011
Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1
BRIC Diabetes Drugs Market
|
|
|
|
